Zydus’ SEZ II, Ahmedabad plant clears USFDA inspection with nil observations
Drug Approval

Zydus’ SEZ II, Ahmedabad plant clears USFDA inspection with nil observations

The inspection concluded with NIL observations

  • By IPP Bureau | August 16, 2025

Zydus announced that the USFDA has completed a Pre-Approval Inspection (PAI) and general cGMP inspection at its formulation manufacturing plant in SEZ II, Ahmedabad. The inspection, conducted from 11 to 13 August 2025 for three products, concluded with no observations.

The inspection concluded with NIL observations.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International